A study of thiotepa, ifosphamide, etoposide and rituximab for the treatment of relapsed or refractory primary central nervous system lymphoma
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Thiotepa (Primary) ; Etoposide; Ifosfamide; Rituximab
- Indications CNS cancer; Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms TIER
- 01 Nov 2021 Status changed from active, no longer recruiting to completed.
- 17 May 2019 Planned End Date changed from 30 Jun 2021 to 31 Oct 2021.
- 03 Apr 2019 Status changed from recruiting to active, no longer recruiting.